“Abstract: Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns…”
Articles that are "open access" in PMC are made available under a Creative Commons or similar license that allows more liberal redistribution and reuse than a traditional copyrighted work. Many articles in PMC are protected by U.S. and/or foreign copyright laws, even though PMC provides free access to it. Some journals use the label "open access" for an article that is available free at time of publication, but is still subject to traditional copyright restrictions. Open access articles are included in the PMC Open Access Subset and can be found in PMC by searching open access[filter].